Abstract
Background Thalassemia syndromes are inherited hemoglobin disorders that result when the synthesis of normal hemoglobin is lacking or significantly reduced. For people with thalassemia, long-term red blood cell transfusion remains the mainstay of therapy, which may lead to iron overload causing severe complications and damage in different body organs. Long-term iron chelation therapy is essential for people with thalassemia to minimize the ongoing iron-loading process. In addition, suboptimal adherence can increase adverse events associated with iron overload and result in increased morbidity, mortality, healthcare utilization and cost of care. Objectives To identify and assess the effects of computer and mobile technology interventions designed to facilitate medication adherence and disease management in individuals with thalassemia, including:-evaluating the effects of using computer and mobile technology interventions for medication adherence and disease management on health and behavioral outcomes;-identifying and assessing the effects of computer and mobile technology interventions specific to different age groups (children, adolescents and adults) and type of modality (e.g. cell phone, the Internet). Search methods We searched CENTRAL (the Cochrane Library), MEDLINE, Embase, CINAHL, PsycINFO, ProQuest Dissertations & Theses Global, Psychology and Behavioral Sciences Collection, Web of Science Science & Social Sciences Conference Proceedings Indexes, IEEE Xplore and ongoing trial databases (22 February 2018). We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Haemoglobinopathies Trials Register (20 June 2019). We also searched for unpublished work in the abstract book of nine major conferences in the related field.
| Original language | English (US) |
|---|---|
| Article number | CD012900 |
| Journal | Cochrane Database of Systematic Reviews |
| Volume | 2019 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 28 2019 |
Funding
We searched the Cystic Fibrosis and Genetic Disorders Group’s Haemoglobinopathies Trials Register using the terms: (thalassaemia OR (haemoglobinopathies AND general)) AND (mobile technology). The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and weekly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Public Health Agency Annual Scientific Meeting (formerly the Caribbean Health Research Council Meeting); and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group’s website. Date of the most recent search of the Haemoglobinopathies Trials Register: 20 June 2019. In addition to the above, we conducted a search of the following databases:· • CENTRAL, Other Reviews (DARE) and Technology Assessments ( HTA) Databases ( the Cochrane Library) ( 22 February 2018) ( www.cochranelibrary.com/); • PubMed (Epub Ahead of Print, In-Process & Other NonIndexed Citations, for recent records not yet added to MEDLINE) ( 22 February 2018) ( www.ncbi.nlm.nih.gov/sites/ entrez); • MEDLINE (OvidSP, Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE, 1946 to 22 February 2018); • Embase (OvidSP, 1974 to 22 February 2018); • CINAHL (EBSCOHost, 1937 to 22 February 2018); • PsycInfo (EBSCOHost, 1900 to 22 February 2018); • ProQuest Dissertations & Theses Global (ProQuest, 1861 to 22 February 2018); • Web of Science & Social Sciences Conference Proceedings Indexes (CPSI-S & CPSSI, 1990 to 22 February 2018); • Institute of Electrical and Electronics Engineers Explore (IEEE Xplore, 1963 to 22 February 2018). • National Institute for Health Research, UK. This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. • Agency for Healthcare Research and Quality, USA. Sherif Badawy was supported by grant number K12HS023011 from the Agency for Healthcare Research and Quality. This project was supported by grant number K12HS023011 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. We thank the National Institute for Health Research for supporting this project, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health. This project was supported by grant number K12HS023011 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. The authors also thank Ms Linda O’Dwyer (Galter Health Sciences Library, Northwestern University Feinberg School of Medicine, Chicago, IL) for her support with the literature search.
ASJC Scopus subject areas
- Pharmacology (medical)